Cross-genotype immunogenicity and antibody-dependent enhancement of KD-382 dengue vaccine in flavivirus-naïve adults.

IF 6.9 1区医学 Q1 IMMUNOLOGY

NPJ Vaccines Pub Date : 2025-07-09 DOI:10.1038/s41541-025-01204-y

Jean Claude Balingit, Motoharu Abe, Ryosuke Suzuki, Dalouny Xayavong, Mya Myat Ngwe Tun, Yuki Takamatsu, Kengo Sonoda, Kouichi Morita

引用次数: 0

Abstract

This exploratory study evaluated the neutralization breadth and potential antibody-dependent enhancement (ADE) risk following a single-dose of the KD-382 live-attenuated tetravalent dengue vaccine over 12 months in flavivirus-naïve healthy adults. Using single-round infectious particles representing 17 dengue virus genotypes, KD-382-induced antibodies demonstrated durable cross-genotype neutralizing activity, with minimal in vitro ADE risk. These findings highlight KD-382's potential for broad protection and underscore the importance of long-term monitoring in dengue-naïve populations.

查看原文本刊更多论文

KD-382登革热疫苗在flavivirus-naïve成人中的跨基因型免疫原性和抗体依赖性增强

本探索性研究评估了flavivirus-naïve健康成人在12个月内单剂量KD-382减毒四价登革热活疫苗后的中和广度和潜在抗体依赖性增强（ADE）风险。利用代表17种登革热病毒基因型的单轮感染颗粒，kd -382诱导的抗体显示出持久的跨基因型中和活性，体外ADE风险最小。这些发现强调了KD-382具有广泛保护的潜力，并强调了在dengue-naïve人群中进行长期监测的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

NPJ Vaccines Immunology and Microbiology-Immunology

CiteScore

11.90

自引率

4.30%

发文量

146

审稿时长

11 weeks

期刊介绍： Online-only and open access, npj Vaccines is dedicated to highlighting the most important scientific advances in vaccine research and development.